AlphaNet Names Martha A. Sanchez Chief Operating Officer

CORAL GABLES, Fla.--(BUSINESS WIRE)--AlphaNet CEO Robert C. Barrett named Martha A. Sanchez as Chief Operating Officer. Sanchez has an extensive background with more than 30 years of experience in both the clinical and management aspects of the healthcare service industry.

"Martha is a perfect fit for the AlphaNet organization"

With a bachelor degree in nursing and an MBA, both from the University of Miami, Sanchez began her career in nursing and risk management eventually moving into a key role as Controller and Director of Clinical Operations with the Health Foundation of South Florida. She continued combining her management, clinical and financial backgrounds during her 11-year stint as CEO of the Miami-Dade Area Health Education Center and as founder and owner of a business consulting firm.

AlphaNet, Inc., founded in 1995, is a unique, innovative organization providing a wide range of customized patient care and integrated support services to thousands of Alpha-1 patients throughout the United States, Puerto Rico and the US Virgin Islands. Alpha-1 (Alpha-1 Antitrypsin Deficiency) is a genetic disorder causing life-threatening liver and lung disease.

"Martha is a perfect fit for the AlphaNet organization," said Barrett. "Her talents and in-depth knowledge of healthcare systems, risk management and not-for-profit operations, combined with her clinical background, make her an industry superstar."

About Alpha-1

Alpha-1 Antitrypsin Deficiency is a leading genetic killer of adults and a leading cause of liver transplants in children. It is estimated that 25 million Americans are undetected carriers of the Alpha-1 gene and may be at risk for lung and/or liver disease. Only 10 percent of the estimated 120,000 with severe deficiency of Alpha-1 have been diagnosed.

Contacts

AlphaNet, Inc.
Robert C. Barrett, 305-648-9540
CEO
www.alphanet.org
 

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.